# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Duke Kahanamoku (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML050-SYN
- Date: 2026-03-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Kawika Lindgren-Morrison, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for establishing care for six weeks of breathlessness, ankle swelling and tiredness five years after a heart attack: examination, ECG, chest X-ray, NT-proBNP and laboratory tests, a diuretic, and the plan for an echocardiogram. **S**

## Objective

NT-proBNP: 2450 pg/mL (high); Sodium: 138 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 1.02 mg/dL; eGFR (CKD-EPI 2021): 81 mL/min/1.73 m²; Glucose: 102 mg/dL (high); Magnesium: 2 mg/dL; Hemoglobin: 13.4 g/dL; Ferritin: 62 ng/mL (low); Transferrin saturation: 16% (low); TSH: 2.1 mIU/L; Hemoglobin A1c: 5.9% (high); Total cholesterol: 168 mg/dL; LDL cholesterol: 92 mg/dL (high); HDL cholesterol: 44 mg/dL; Triglycerides: 160 mg/dL (high); ALT: 28 U/L; PHQ-2: 1; KCCQ-12 overall summary: 38. All results are synthetic.

BP 142/86 mmHg; pulse 92 bpm; respirations 20/min; temperature 36.7 °C; oxygen saturation 94% on room air; weight 97.6 kg; BMI 28.5 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Breathlessness on exertion for six weeks (paddling out, walking uphill, finishing his morning swim), with ankle swelling by evening and tiredness, five years after a heart attack; cause to be determined; Coronary artery disease with an old anterior myocardial infarction five years ago, treated with medicines; synthetic modern episode linked to the documented heart attack of 1952; Iron deficiency without anemia (ferritin 62 ng/mL, transferrin saturation 16%). Strengths and supports remain part of the care plan. **S**

## Medication changes

- Continued without change: Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Stopped: Atorvastatin 40 mg oral tablet, one tablet daily **S**
- Started: Atorvastatin 80 mg oral tablet, one tablet daily **S**
- Continued without change: Metoprolol tartrate 25 mg oral tablet, one tablet twice daily **S**
- Continued without change: Lisinopril 10 mg oral tablet, one tablet daily **S**
- Started: Furosemide 40 mg oral tablet, one tablet every morning **S**

## Plan

- Culturally safe care: address him as Mr. Kahanamoku, as he asked; take time; explain each test and medicine plainly; involve his ʻohana as he chooses while he makes the decisions. Guideline: Potentially Preventable Hospitalizations for Congestive Heart Failure Among Asian Americans and Pacific Islanders in Hawaiʻi (2015); Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026) **S**
- Heart failure cardiology consultation on the day of the two-week visit, with an echocardiogram, to confirm the diagnosis and its cause and to plan guideline-directed medical therapy, ischemic evaluation and device decisions. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026) **S**
- Furosemide 40 mg every morning for congestion, with a daily weight and a written plan; metabolic panel and magnesium in one to two weeks; lower the dose when he is dry. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026) **S**
- Baseline tests: ECG, chest X-ray, NT-proBNP, metabolic panel and magnesium, blood count, iron studies, TSH, hemoglobin A1c, lipids and ALT; echocardiogram at the two-week visit. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026) **S**
- Atorvastatin raised from 40 to 80 mg for LDL 92 mg/dL; lipid panel in four to twelve weeks; goal below 70 mg/dL. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026) **S**
- Sodium: less salted and dried fish, shoyu and salty party food, using the foods he already eats; no routine fluid restriction; daily weights. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022) **S**
- Vaccinations: pneumococcal, influenza, COVID-19 and RSV as due, because heart disease raises the risk of severe respiratory infection. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); Adult Immunization Schedule by Age (2026) **S**
- Native Hawaiian healing alongside clinic care, if he wishes: lomilomi through Ke Ola Mamo, a Native Hawaiian Health Care System; he will tell the clinic before using any plant medicine so that interactions can be checked; the clinic asks nothing further about his practices. Guideline: Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026) **S**
